Related Experiment Video

Updated: May 29, 2026

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

The PPAR-γ agonist troglitazone antagonizes survival pathways induced by STAT-3 in recombinant interferon-β treated

Giovanni Vitale1, Silvia Zappavigna, Monica Marra

  • 1Dipartimento di Scienze Mediche, Universita` degli Studi di Milano, Milan, Italy. giovanni.vitale@unimi.it

Biotechnology Advances
|August 30, 2011
PubMed

Insights

Combining interferon-beta (IFN-β) with troglitazone synergistically inhibits pancreatic cancer growth by blocking survival pathways and promoting cell death. This approach overcomes cancer cell resistance to IFN-β, offering a novel therapeutic strategy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Cancer cells evade apoptosis via ras→MAPK pathways, resisting type I interferons (IFNs).
  • IFN signaling involves STATs, regulated by PPAR-γ, suggesting potential therapeutic interactions.

Purpose of the Study:

  • To investigate the synergistic effects of recombinant IFN-β and the PPAR-γ agonist troglitazone (TGZ) on pancreatic cancer cells.
  • To elucidate the molecular mechanisms underlying the combination therapy's efficacy.

Main Methods:

  • Treatment of BxPC-3 pancreatic cancer cells with IFN-β and TGZ.
  • Analysis of signaling pathways including STAT-3, MAPK, AKT, and PPAR-γ activation.
  • Assessment of cell cycle progression, apoptosis, and autophagy markers.

Main Results:

  • The combination therapy synergistically inhibited cancer cell growth, inducing G0/G1 cell cycle arrest via increased p21 and p27.
  • TGZ counteracted IFN-β-induced STAT-3 and MAPK activation, enhancing anti-cancer effects.
  • Combination treatment increased autophagy and decreased bcl-2/beclin-1 complex formation by inhibiting AKT→mTOR.

Conclusions:

  • PPAR-γ activation counteracts STAT-3-dependent escape pathways, enhancing IFN-β-induced growth inhibition in pancreatic cancer.
  • The combination therapy induces cell cycle arrest and promotes autophagic cell death.
  • This study presents the first evidence of PPAR-γ's role in overcoming IFN-β resistance in pancreatic cancer.

Related Concept Videos

TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...